SLC5A2 and myocardial infarction: In diabetic kidney disease (DKD) patients, SGLT2 inhibitors were found to decrease the risks of all-cause mortality, renal events (declining GFR, worsening creatinine, ESRD, or death from renal or cardiovascular causes), hospitalization for heart failure (HHF), and major adverse cardiovascular events (MACE) including myocardial infarction (MI), stroke, or cardiovascular mortality [63].